Galectin Therapeutics Inc宣布，其候选药物Belapectin的NAVIGATE二期B阶段临床试验结果，已正式发表于权威期刊《肝脏病学杂志》。
该试验旨在评估Belapectin治疗非酒精性脂肪性肝炎（NASH）伴肝硬化患者的疗效与安全性。此次发表标志着该药物的重要临床数据获得了同行评审的认可，并进入了更广泛的科学界视野。研究结果的详细披露，将为后续的临床开发路径提供关键的学术依据。
这一里程碑事件，不仅强化了Belapectin作为潜在NASH疗法的科学基础，也提升了Galectin Therapeutics在该领域的能见度。公司将继续推进相关临床项目，以应对这一尚未满足重大医疗需求的疾病领域。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.